HC Wainwright Issues Negative Estimate for RMTI Earnings

Rockwell Medical, Inc. (NASDAQ:RMTI - Free Report) - Equities researchers at HC Wainwright cut their Q2 2025 earnings per share (EPS) estimates for Rockwell Medical in a report issued on Monday, November 25th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($0.01) per share for the quarter, down from their prior forecast of $0.02. HC Wainwright currently has a "Buy" rating and a $7.00 target price on the stock. The consensus estimate for Rockwell Medical's current full-year earnings is ($0.03) per share. HC Wainwright also issued estimates for Rockwell Medical's Q3 2025 earnings at ($0.01) EPS and Q4 2025 earnings at $0.01 EPS.

A number of other equities research analysts have also issued reports on RMTI. Rodman & Renshaw began coverage on Rockwell Medical in a research report on Thursday, November 14th. They issued a "buy" rating and a $5.00 price target for the company. StockNews.com cut Rockwell Medical from a "buy" rating to a "hold" rating in a report on Thursday, November 21st. Finally, RODMAN&RENSHAW upgraded Rockwell Medical to a "strong-buy" rating in a report on Thursday, November 14th.

Rockwell Medical Price Performance

RMTI stock traded down $0.06 during mid-day trading on Tuesday, reaching $2.25. The company's stock had a trading volume of 788,873 shares, compared to its average volume of 382,379. The company has a current ratio of 2.41, a quick ratio of 2.00 and a debt-to-equity ratio of 0.33. The company's 50 day moving average is $3.50 and its two-hundred day moving average is $2.66. Rockwell Medical has a fifty-two week low of $1.16 and a fifty-two week high of $5.15. The stock has a market cap of $72.72 million, a PE ratio of -46.20 and a beta of 1.50.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Armistice Capital LLC raised its position in Rockwell Medical by 22.5% in the second quarter. Armistice Capital LLC now owns 3,221,640 shares of the company's stock valued at $5,670,000 after purchasing an additional 592,000 shares during the period. Jane Street Group LLC purchased a new stake in shares of Rockwell Medical in the 3rd quarter valued at $534,000. Walleye Capital LLC acquired a new position in Rockwell Medical during the 3rd quarter worth about $435,000. Renaissance Technologies LLC boosted its holdings in Rockwell Medical by 877.1% during the 2nd quarter. Renaissance Technologies LLC now owns 102,700 shares of the company's stock valued at $181,000 after acquiring an additional 92,189 shares during the period. Finally, Corsair Capital Management L.P. acquired a new position in Rockwell Medical in the 3rd quarter valued at about $298,000. Institutional investors and hedge funds own 23.31% of the company's stock.

Rockwell Medical Company Profile

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.